None
Conditions
Interventions
Remimazolam +0.02mg/kg oxalidine fumarate group:0.02mg/kg oliceridine+ remimazolam
Remimazolam +0.025mg/kg oxalidine fumarate group:0.025mg/kg oliceridine+ remimazolam
Sponsors
Affiliated Shunde Hospital of Jinan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 60 years old, with a body mass index (BMI) ranging from 18 to 28 kg/m², Mallampati grade ? or ?, and no abnormalities in airway, head and neck conditions. 2. American Society of Anesthesiologists (ASA) score of grade I or II. 3. Patients scheduled for hysteroscopy. 4. Patients volunteer to participate in this study. 5. Having not taken sedative and analgesic drugs recently, with no history of mental and neurological diseases, and no history of severe heart, lung, liver and kidney diseases.
Exclusion criteria
Exclusion criteria: 1.Patients who refused to participate or were not suitable to participate in this trial; 2.Those with contraindications for anesthesia and surgery; 3.Those who used anesthetic drugs, sedatives or opioid drugs within 24 hours before surgery; 4.Patients with myasthenia gravis; 5.Patients in a severe depressive state; 6.Those allergic to benzodiazepines; 7.Patients with liver and kidney dysfunction combined with endocrine and metabolic diseases; 8.Those accompanied by mental and neurological diseases; 9.Those without obtaining the informed consent of the patients; 10 Those with unstable vital signs due to various serious diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose of remimazolam; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate;Breathing;Recovery time;Adverse reactions; | — |
Countries
China
Contacts
Public ContactZheng Yuling
Affiliated Shunde Hospital of Jinan University
Outcome results
None listed